A "Catastrophic" Heparin-Induced Thrombocytopenia

Area of Science:

• Immunology
• Hematology
• Vascular Medicine

Background:

• Heparin-induced thrombocytopenia (HIT) is an antibody-mediated syndrome triggered by heparin exposure, paradoxically causing thrombosis instead of bleeding.
• HIT antibodies target complexes of heparin (unfractionated or low-molecular-weight) and platelet factor 4 (PF4).
• This immune complex activates platelets and endothelial cells, leading to procoagulant release and coagulation cascade activation.

Observation:

• A case report details a patient who developed severe HIT after enoxaparin exposure during knee replacement and urosepsis.
• The patient experienced extensive arterial and venous thromboses across cerebral, pulmonary, hepatic, and leg vasculature.
• This severe presentation was successfully managed with fondaparinux, preventing further thrombotic or bleeding events.

Findings:

• HIT can manifest with a thrombotic burden comparable to catastrophic antiphospholipid syndrome.
• Differential diagnosis is crucial to avoid inappropriate platelet transfusions in HIT patients.
• Fondaparinux, though used off-label, demonstrated efficacy and simplicity in treating this severe HIT case.

Implications:

• Recognizing severe HIT presentations is vital for timely and appropriate management.
• The findings support considering fondaparinux as a treatment for severe HIT.
• This case highlights the need for careful differential diagnosis in thrombocytopenic patients with thrombotic events.